Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Claud B who wrote (2142)	1/29/1998 8:58:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 7041

Note of Caution: ORG recommended for approval despite lots of charges against their technology and their deals. Novartis had access to the data (like Schering ?), but the public did not. Novartis put $ millions, the shorts will be in trouble tomorrow. Sturza made great arguments against the approval (he shorted well with Lipo)but maybe not this one. CORR was a darling of analysts, 11,000 patients ( but only a small 1.5% difference in the clinical trial) FDA approval with severe restrictions, even the dose was lowered. Drugs an biotechs (plus/minus FDA) could fool the sharpest. BigKNY3, maybe phantolamine gets approved and the "blue" halo drug does not. Maybe Asencio is wrong (he likes the "blue" vision business drug).